Skip to main content

Home/ Cancer/ Group items tagged October

Rss Feed Group items tagged

Matti Narkia

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer - British J... - 1 views

  •  
    Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.
    Michelakis ED, Webster L, Mackey JR.
    Br J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review.
    PMID: 18766181
    doi:10.1038/sj.bjc.6604554

    The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a (potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials

    More than 40 nonrandomised trials of DCA in small cohorts of patients have been reported, but the first two randomised control trials of chronic oral therapy with DCA in congenital mitochondrial diseases were reported in 2006. In the first, a blinded placebo-controlled study was performed with oral DCA administered at 25 mg kg-1 day-1 in 30 patients with MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (Kaufmann et al, 2006). Most patients enrolled in the DCA arm developed symptomatic peripheral neuropathy, compared with 4 out of 15 in the placebo arm, leading to the termination of the study. Seventeen out of 19 patients had at least partial resolution of peripheral neurological symptoms by 9 months after discontinuation of DCA. This neurotoxicity res
Matti Narkia

A systematic review of the anticancer properties of berberine, a natural product from C... - 0 views

  •  
    A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs.
    Sun Y, Xun K, Wang Y, Chen X.
    Anticancer Drugs. 2009 Oct;20(9):757-69.
    PMID: 19704371
Matti Narkia

Mechanisms of Berberine (Natural Yellow 18)-Induced Mitochondrial Dysfunction: Interact... - 0 views

  •  
    Mechanisms of berberine (natural yellow 18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator.
    Pereira CV, Machado NG, Oliveira PJ.
    Toxicol Sci. 2008 Oct;105(2):408-17. Epub 2008 Jul 3.
    PMID: 18599498
    doi: 10.1124/jpet.107.128017

    The data from the present work appear to show that berberine also presents some degree of toxicity to "nontumor" systems, which should be carefully understood. ANT inhibition in nontumor cells by berberine would be responsible for a decrease in energy production and could also result in MPT induction. To the best of our knowledge, no full toxicity assessment exists for berberine in humans, although its use in several commercially available supplements suggests that the compound may present a relatively wide safety interval. In fact, a study with patients with congestive heart failure treated with 1.2 g/day of oral berberine revealed low toxicity and resulted into an average plasma concentration of 0.11 mg/l which would translate into 0.3µM (Zeng and Zeng, 1999Go). Repeated cumulative treatments, alternative forms of formulation (e.g., topical application vs. injection) or more importantly, active mitochondrial accumulation due to its positive charge would be expected to increase its concentration in cells into the range of concentrations used in this study.

    Empirical data from nontraditional medicines plus the use of extensive clinical assays would allow the use of berberine as a promising antimelanoma agent while maintaining its safety for humans. In radial/vertical forms of melanoma, a possible topical application of berberine would also be possible, thus minimizing side effects on other organs.

    In conclusion, the present work identifies the ANT as an important target for berberine, with clear relevance for its proposed antitumor effects.
Matti Narkia

Berberine Inhibits Metastasis of Nasopharyngeal Carcinoma 5-8F Cells by Targeting Rho K... - 0 views

  •  
    Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567.
    Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, Wu B, Liu S, Tian D, Zhu F, He Z, Deng F, Cao Y.
    J Biol Chem. 2009 Oct 2;284(40):27456-66. Epub 2009 Aug 3.
    PMID: 19651779
Matti Narkia

Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinom... - 0 views

  •  
    Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP.
    Mantena SK, Sharma SD, Katiyar SK.
    Carcinogenesis. 2006 Oct;27(10):2018-27. Epub 2006 Apr 18.
    PMID: 16621886
    doi:10.1093/carcin/bgl043

    In the present investigation, we show that berberine, which is present abundantly in Berberis plant species, significantly inhibits the viability, proliferation and induces cell death in human epidermoid carcinoma A431 cells (Figure 1), but this effect was not found in normal human epidermal keratinocytes under the identical conditions, except for a non-significant reduction in cell viability at higher concentrations of berberine (50 and 75 µM) and treatment of cells for a longer period of time (72 h). These data suggested that berberine may be examined as an effective chemotherapeutic agent against non-melanoma skin cancers.

    In conclusion, our study indicates that berberine inhibits growth, induces G1 arrest and apoptotic cell death of human epidermoid carcinoma A431 cells. We also provide mechanistic evidences that berberine-induced apoptosis in human epidermoid carcinoma cells is mediated through disruption of mitochondrial membrane potential and activation of caspase 3 pathway, although other pathways may have a role and that require further investigation. Moreover, further in vivo studies are required to determine whether berberine could be an effective chemotherapeutic agent for the prevention of non-melanoma skin cancers.
Matti Narkia

Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional ... - 0 views

  •  
    Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations.
    Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y.
    J Ethnopharmacol. 2009 Oct 29;126(1):5-17. Epub 2009 Aug 15.
    PMID: 19686830
    doi:10.1016/j.jep.2009.08.009

    Conclusions
    The modern evidences of treating cancer with Huanglian and berberine have a strong linkage with traditional concept and rules of using Huanglian in CM practice. As anticancer candidates with low toxicity, berberine and its altered structure, as well as Huanglian and its formulae, will attract scientists to pursue the potential anticancer effects and the mechanisms by using technologies of genomics, proteomics and other advanced approaches. On the other hand, relatively few in vivo studies have been conducted on anticancer effects of Huanglian and berberine. The clinical application of berberine or Huanglian as novel cancer therapeutic agents requires in vivo validations and further investigations of their anticancer mechanisms.
Matti Narkia

A systematic review of the anticancer properties of berberine, a natural product from C... - 0 views

  •  
    A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs.
    Sun Y, Xun K, Wang Y, Chen X.
    Anticancer Drugs. 2009 Oct;20(9):757-69.
    PMID: 19704371
Matti Narkia

Meta-analysis of vitamin D, calcium and the prevention of breast cancer. - [Breast Canc... - 0 views

  •  
    Meta-analysis of vitamin D, calcium and the prevention of breast cancer.
    Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H.
    Breast Cancer Res Treat. 2009 Oct 23. [Epub ahead of print]
    PMID: 19851861

    These results provide strong evidence that vitamin D and calcium have a chemopreventive effect against breast cancer.
Matti Narkia

Women With Breast Cancer Have Low Vitamin D Levels - 0 views

  •  
    "ScienceDaily (Oct. 8, 2009) - Women with breast cancer should be given high doses of vitamin D because a majority of them are likely to have low levels of vitamin D, which could contribute to decreased bone mass and greater risk of fractures, according to scientists at the University of Rochester Medical Center."

    Scientists funded by the NCI analyzed vitamin D levels in each woman, and the average level was 27 nanograms per milliliter; more than two-thirds of the women had vitamin deficiency. Weekly supplementation with high doses of vitamin D -- 50,000 international units or more -- improved the levels, according to Peppone's study.

    The U.S. Institute of Medicine suggests that blood levels nearing 32 nanograms per milliliter are adequate.
Matti Narkia

Experimental Drug May Work In Many Cancers - 2 views

  •  
    "SCIENTISTS have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today. "
Matti Narkia

Factors Associated With Clinical Benefit From Epidermal Growth Factor Receptor Inhibito... - 0 views

  •  
    Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
    Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE.
    Oral Oncol. 2009 Oct;45(10):e155-60. Epub 2009 Jul 7.
    PMID: 19586795
Matti Narkia

Calcium, Dairy Foods, Vitamin D, and Colorectal Cancer Risk: The Fukuoka Colorectal Can... - 0 views

  •  
    Calcium, dairy foods, vitamin D, and colorectal cancer risk: the Fukuoka Colorectal Cancer Study.
    Mizoue T, Kimura Y, Toyomura K, Nagano J, Kono S, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Yasunami Y, Maekawa T, Takenaka K, Ichimiya H, Imaizumi N.
    Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2800-7.
    PMID: 18843026
Matti Narkia

Vitamin D From Dietary Intake and Sunlight Exposure and the Risk of Hormone-Receptor-De... - 0 views

  •  
    Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer.
    Blackmore KM, Lesosky M, Barnett H, Raboud JM, Vieth R, Knight JA.
    Am J Epidemiol. 2008 Oct 15;168(8):915-24. Epub 2008 Aug 27.
    PMID: 18756015
    doi:10.1093/aje/kwn198

    This study suggests that vitamin D is associated with a reduced risk of breast cancer regardless of ER/PR status of the tumor. Future studies with a larger number of receptor-negative and mixed tumors are required.
Matti Narkia

Vitamin D Is Associated with Improved Survival in Early-Stage Non-Small Cell Lung Cance... - 0 views

  •  
    Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients.
    Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Giovannucci E, Christiani DC.
    Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2303-9.
    PMID: 16214909

    In conclusion, the joint effects of surgery season and recent vitamin D intake seem to be associated with the survival of early-stage non-small cell lung cancer patients.
Matti Narkia

Modulatory effects of EPA and DHA on proliferation and apoptosis of pancreatic cancer c... - 0 views

  •  
    It was concluded that omega-3 fatty acid could inhibit the proliferation of pancreatic cancer cell line SW1990 cells and promote their apoptosis. The down-regulation of the cyclin E expression by omega-3 fatty acid might be one of the mechanisms for its anti-tumor effect on pancreatic cancer.

    Modulatory effects of EPA and DHA on proliferation and apoptosis of pancreatic cancer cells.
    Zhang W, Long Y, Zhang J, Wang C.
    J Huazhong Univ Sci Technolog Med Sci. 2007 Oct;27(5):547-50.
    PMID: 18060632
Matti Narkia

Maté: a risk factor for oral and oropharyngeal cancer - Oral Oncol. 2002 Oct;... - 0 views

  •  
    Maté: a risk factor for oral and oropharyngeal cancer.
    Goldenberg D.
    Oral Oncol. 2002 Oct;38(7):646-9. Review.
    PMID: 12167417

Matti Narkia

Scripps research team solves structure of 'beneficial' virus | Eureka! Science News - 0 views

  •  
    D structure of the virus, known as Seneca Valley Virus-001, reveals that it is unlike any other known member of the Picornaviridae viral family, and confirms its recent designation as a separate genus "Senecavirus." The new study reveals that the virus's outer protein shell looks like a craggy golf ball¬-one with uneven divets and raised spikes-and the RNA strand beneath it is arranged in a round mesh rather like a whiffleball. "It is not at all like other known picornaviruses that we are familiar with, including poliovirus and rhinoviruses, which cause the common cold," says the study's senior author, Associate Professor Vijay S. Reddy, Ph.D., of The Scripps Research Institute. "This crystal structure will now help us understand how Senecavirus works, and how we can take advantage of it."

    The Senecavirus is a "new" virus, discovered several years ago by Neotropix Inc., a biotech company in Malvern, Pennsylvania. It was at first thought to be a laboratory contaminant, but researchers found it was a pathogen, now believed to originate from cows or pigs. Further investigation found that the virus was harmless to normal human cells, but could infect certain solid tumors, such as small cell lung cancer, the most common form of lung cancer.
Matti Narkia

Multi-targeted therapy of cancer by omega-3 fatty acids - Cancer Lett. 2008 Oct 8 - 0 views

  •  
    Multi-targeted therapy of cancer by omega-3 fatty acids.
    Berquin IM, Edwards IJ, Chen YQ.
    Cancer Lett. 2008 Oct 8;269(2):363-77. Epub 2008 May 13. Review.
    PMID: 18479809
    doi:10.1016/j.canlet.2008.03.044
Matti Narkia

Vitamin D and cancer Ali MM, Vaidya V - J Can Res Ther 2007 Oct-Dec - 0 views

  •  
    Vitamin D and cancer.
    Ali MM, Vaidya V.
    J Cancer Res Ther. 2007 Oct-Dec;3(4):225-30. Review.
    PMID: 18270398
    DOI: 10.4103/0973-1482.38998
Matti Narkia

Arginine and cancer. - J Nutr. 2004 Oct - 0 views

  •  
    Arginine and cancer.
    Lind DS.
    J Nutr. 2004 Oct;134(10 Suppl):2837S-2841S; discussion 2853S. Review.
    PMID: 15465796
1 - 20 of 27 Next ›
Showing 20 items per page